IP Library Granted Patent US 10,206,944
Granted Patent B2
US 10,206,944 · App. 14/400,069 · Granted Feb 19, 2019

Chondroitin for use in medicine

Inventors: Mario De Rosa (Lugano, CH); Chiara Schiraldi (Lugano, CH)
Assignee: ALTERGON S.A.
A61K31/726A61K31/715
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,944
App. No.
14/400,069
Granted
Feb 19, 2019
Kind
B2
Abstract

Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.

Claims (4)

1. Pharmaceutical, nutraceutical, cosmeceutical compositions or medical devices in a form selected from the group consisting of capsules, tablets, eye drops, gel, creams, solutions or suspensions, mouth soluble powders, spray and syrups, said compositions comprising non sulphated chondroitin and hyaluronic acid as the active ingredient.

2. Compositions according to claim 1 further comprising other active ingredients.

3. Compositions according to claim 1 for use selected from the group consisting of wound repair, treatment of articular, ocular, oncological pathologies, pathologies of the respiratory apparatus, osteoarthritis, interstitial cystitis, cutaneous senescence, osmotic and protective agent in solutions for intraperitoneal dialysis and scaffold for the growth of 3D cell cultures.

4. Compositions according to claim 3 for use selected from the group consisting of articular viscosupplementation and repair of cartilaginous tissue, cutaneous biorivitalizazion by means of intradermal microinjections, treatment of dry eye disease and application of contact lenses.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2025
From: ALTERGON SA
To: IBSA INSTITUT BIOCHIMIQUE SA
Reel/Frame 071736/0261 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADD A SECOND ASSIGNOR PREVIOUSLY RECORDED ON REEL 034135 FRAME 0127. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 11, 2014
From: DE ROSA, MARIO; SCHIRALDI, CHIARA
To: ALTERGON S.A.
Reel/Frame 034205/0973 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2014
From: DE ROSA, MARIO
To: ALTERGON S.A.
Reel/Frame 034135/0127 →
Priority Claims (1)
IT MI2012A0896 · May 23, 2012 · national
Continuity (1)
Related Publication 20150258134A1 · Sep 17, 2015
Cited By (2)
US 12,310,981 US 12,440,510